Approximately 5,000 people in the U.S. develop amyotrophic lateral sclerosis (ALS) each year. On average, they survive for ...

Approximately 5,000 people in the U.S. develop amyotrophic lateral sclerosis (ALS) each year. On average, they survive for only two to five years after being diagnosed, according to the Centers for ...

Researchers have uncovered a mechanism that may trigger ALS’s earliest stages, identifying proteins that mislocalize, causing ...

Research indicates that dried seeds of the jujube plant, Ziziphus jujuba, may help restore cognitive and motor functions in ...

Targeting ceramide synthase enzymes may reduce multiple sclerosis severity by limiting ceramide C16 synthesis, offering ...

A team of researchers has uncovered a groundbreaking mechanism in the formation of harmful protein aggregates that lead to neurodegenerative diseases such as Parkinson's Disease. The team, led by ...

Glaucoma drug methazolamide shows potential in fighting neurodegenerative diseases, offering new hope for treating conditions ...

The link between lipid metabolism and glaucoma pathophysiology could guide future research and treatment strategies.

UB nursing professor Carleara Weiss will focus on the link among biomarkers of neurodegeneration, sleep disturbances and cognitive decline.

A randomised clinical trial found that reduced iron may accelerate cognitive decline in early-stage Alzheimer’s disease.

In September 2024, Athira announced topline results from the LIFT-AD Phase 2/3 clinical trial of fosgonimeton in mild-to-moderate Alzheimer’s disease. The study did not meet its primary or key ...

Impressively, 5-ALA treatment not only prevented α-synuclein aggregation but also halted the progression of motor symptoms, a ...